After some suspense — a PDUFA date came and went with no announcement — esketamine (Spravato) nasal spray won approval for treatment-resistant depression, in combination with a standard antidepressant.
The FDA also approved extended-released methylphenidate hydrochloride capsules (Adhansia XR) for pediatric and adult patients with ADHD, Adlon Therapeutics announced.
Regular microdoses of psychedelic hallucinogen DMT (dimethyltryptamine) helped reduce anxiety and depression symptoms in rats. (ACS Chemical Neuroscience)
Roughly 25% of people with bipolar disorder might be prescribed the wrong medications — specifically antidepressants that could worsen mania, a Scottish study found. (BBC)
Diabulimia — a form of eating disorder where people with type 1 diabetes give themselves less insulin to lose weight — is gaining popularity and new programs are popping up in response. (The BMJ)
A rehab center in Scotland is now treating patients for “Bitcoin addiction.” (CCN)
Many seniors may be missing out on cognitive screening for dementia, despite the Alzheimer’s Association recommending it as part of an annual wellness exam for adults 65 and older. (NPR)
The FDA issued a warning letter to one of Teva’s manufacturing plants for issues involving faulty laser drilling in its paliperidone generic. (FiercePharma)
School services may be lacking for a large portion of kids with ADHD. (ScienceDaily)